Skip to main content

Table 2 Dengue antibody GMTs and seropositivity status in the “standard” dengue vaccination schedule (Group 1) versus the “compressed” dengue vaccination schedule (Group 2)

From: Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults

Time point

Group 1 (N = 117)

Group 2 (N = 119)

n

GMT (95% CI)

Seropositive, % (95% CI)

n

GMT (95% CI)

Seropositive, % (95% CI)

Serotype 1

 Baseline

117

5.38 (4.85–5.96)

1.7 (0.2–6.0)

119

5.13 (4.98–5.28)

2.5 (0.5–7.2)

 28 days post-dose 3

93

14.8 (11.3–19.4)

52.7 (42.1–63.1)

108

15.9 (12.6–20.0)

56.5 (46.6–66.0)

 6 months post-dose 3

88

13.3 (10.2–17.4)

47.7 (37.0–58.6)

104

9.01 (7.54–10.8)

32.7 (23.8–42.6)

Serotype 2

 Baseline

117

5.19 (4.82–5.58)

0.9 (0.0–4.7)

119

5.22 (4.96–5.50)

2.5 (0.5–7.2)

 28 days post-dose 3

94

51.2 (38.2–68.6)

84.0 (75.0–90.8)

108

59.9 (45.8–78.4)

88.0 (80.3–93.4)

 6 months post-dose 3

88

45.6 (31.6–65.6)

75.0 (64.6–83.6)

104

38.7 (29.5–50.8)

80.8 (71.9–87.8)

Serotype 3

 Baseline

117

5.32 (4.94–5.73)

2.6 (0.5–7.3)

119

5.28 (5.03–5.55)

4.2 (1.4–9.5)

 28 days post-dose 3

94

45.7 (35.0–59.8)

85.1 (76.3–91.6)

107

59.3 (47.0–74.7)

90.7 (83.5–95.4)

 6 months post-dose 3

88

30.2 (22.8–40.2)

79.5 (69.6–87.4)

104

34.5 (27.5–43.3)

80.8 (71.9–87.8)

Serotype 4

 Baseline

117

5.78 (5.16–6.48)

6.8 (3.0–13.0)

119

5.11 (4.90–5.33)

0.8 (0.0–4.6)

 28 days post-dose 3

94

66.8 (50.9–87.8)

88.3 (80.0–94.0)

107

83.1 (61.4–112.0)

86.0 (77.9–91.9)

 6-months post-dose 3

88

74.8 (54.9–102.0)

86.4 (77.4–92.8)

104

41.7 (31.2–55.9)

74.0 (64.5–82.1)

≥ 3 serotypes

 Baseline

117

NA

0.9 (0.0–4.7)

119

NA

0.8 (0.0–4.6)

 28 days post-dose 3

94

NA

73.4 (63.3–82.0)

108

NA

82.4 (73.9–89.1)

 6-months post-dose 3

88

NA

64.8 (53.9–74.7)

104

NA

58.7 (48.6–68.2)

All 4 serotypes

 Baseline

117

NA

0.9 (0.0–4.7)

119

NA

0.8 (0.0–4.6)

 Post-dose 3

94

NA

50.0 (39.5–60.5)

108

NA

42.6 (33.1–52.5)

 6-months post-dose 3

88

NA

43.2 (32.7–54.2)

104

NA

26.9 (18.7–36.5)

  1. Seropositive defined as antibody titres ≥10 (1/dil) against each serotype, and against at least 3 or all 4 serotypes with the parental dengue virus strain
  2. GMT geometric mean titre, n number of participants with available data for endpoint, NA not applicable